| Cash flow (USD) | Q2 2026 ended Jun 30, 2026 | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | -1.33B | -4.24B | 2.96B | 5.79B | 4.43B | 5.08B | 3.74B | 3.16B |
| Depreciation and amortization | 599.00M | 581.00M | 1.49B | 532.00M | 518.00M | 502.00M | 522.00M | 553.00M |
| Stock-based compensation | 298.00M | 185.00M | 205.00M | 204.00M | 216.00M | 195.00M | 187.00M | 195.00M |
| Cash from operations | 5.37B | 3.92B | 2.86B | 7.82B | 3.29B | 2.50B | 3.45B | 9.29B |
| Capital expenditure | -893.00M | -991.00M | -1.03B | -987.00M | -764.00M | -1.33B | -937.00M | -783.00M |
| Free cash flow | 4.48B | 2.93B | 1.82B | 6.83B | 2.53B | 1.17B | 2.51B | 8.51B |
| Acquisitions | 0 | -8.78B | -10.04B | 0 | 0 | 0 | 1.34B | -598.00M |
| Cash from investing | -5.60B | -10.21B | -11.20B | -283.00M | -770.00M | -1.49B | -1.44B | -3.85B |
| Dividends paid | -2.14B | -2.10B | -2.02B | -2.03B | -2.08B | -2.05B | -1.95B | -1.95B |
| Share buybacks | -757.00M | -874.00M | -1.25B | -1.32B | -1.34B | -1.16B | -489.00M | -444.00M |
| Net debt issued | -5.00M | -1.14B | 7.92B | 5.96B | 0 | -2.50B | -539.00M | -1.00M |
| Cash from financing | 1.76B | -2.98B | 4.75B | 2.64B | -3.56B | -5.75B | -3.01B | -2.42B |
| Net change in cash | 1.49B | -9.29B | -3.57B | 10.19B | -659.00M | -4.59B | -1.37B | 3.31B |
From Merck's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.